iEmoji Feeds @Manni Mohyuddin (ManniMD1)

1.

ManniMD1
Manni Mohyuddin @ManniMD1
Also perhaps disappointingly, the ide-cel curve shows no signs of cure/plateau .

Everyone eventually progresses twitter.com/i/web/status/1…
10 Feb 23 copy & paste +upvote -downvote Also perhaps disappointingly, the ide-cel curve shows no signs of cure/plateau . Everyone eventually progresses 💔… https://t.co/aYnjOIrpPu

2.

ManniMD1
Manni Mohyuddin @ManniMD1
Grateful to have contributed to this project
Hoping for some positive changes in oncology news reporting!… twitter.com/i/web/status/1…
Retweet of status by @KarunNeupaneMD
15 Feb 23 copy & paste +upvote -downvote Grateful to have contributed to this project 🙏 Hoping for some positive changes in oncology news reporting!… https://t.co/DwlWOh9ONA
3.
ManniMD1
Manni Mohyuddin @ManniMD1
Should be a quality-metrics for academics in oncology: how many papers have you written on your own? Important twitter.com/VPrasadMDMPH/s…
Retweet of status by @mdlhenning
03 Feb 23 copy & paste +upvote -downvote Should be a quality-metrics for academics in oncology: how many papers have you written on your own? Important 👇 https://t.co/gCS9UqcUIc
4.
ManniMD1
Manni Mohyuddin @ManniMD1
Selinexor led to more deaths when added for elderly pts with AML.

nature.com/articles/s4137…

Trial NOT powered for… twitter.com/i/web/status/1…
23 Jul 22 copy & paste +upvote -downvote Selinexor led to more deaths when added for elderly pts with AML. https://t.co/TpLCkbiq96 ⭐️Trial NOT powered for… https://t.co/sLWgeMzlY3
5.
ManniMD1
Manni Mohyuddin @ManniMD1
Interesting analysis-but retrospective conundrum remains

Those who got lower carfilzomib dose had PFS. Was it… twitter.com/i/web/status/1…
06 Jul 22 copy & paste +upvote -downvote Interesting analysis-but retrospective conundrum remains❓ Those who got lower carfilzomib dose had ⬇️ PFS. Was it… https://t.co/mgjKjudtiA
6.
ManniMD1
Manni Mohyuddin @ManniMD1
A thoughtful @VincentRK on difficulties encountered/how to get 1st RCT >20 yrs ago #MedTwitter

What is the sta… twitter.com/i/web/status/1…
Retweet of status by @HadidiSamer
24 Jun 22 copy & paste +upvote -downvote A thoughtful 🧵👇 @VincentRK on difficulties encountered/how to get 1st RCT >20 yrs ago #MedTwitter What is the sta… https://t.co/2W1R02lPsy
7.
ManniMD1
Manni Mohyuddin @ManniMD1
JUST OUT: ATLAS study #ASCO22.

A

KRD versus Len maint after auto-SCT in #mmsm

Better PFS with KRD (no surprise… twitter.com/i/web/status/1…
26 May 22 copy & paste +upvote -downvote JUST OUT: ATLAS study #ASCO22. A 🧵 KRD versus Len maint after auto-SCT in #mmsm Better PFS with KRD (no surprise… https://t.co/XrYfQOgOyP
8.
ManniMD1
Manni Mohyuddin @ManniMD1
Check out my correspondence on OCEAN trial and the authors reply #mmsm @TheLancetHaem
thelancet.com/journals/lanha…
Retweet of status by @HadidiSamer
29 Mar 22 copy & paste +upvote -downvote Check out my correspondence on OCEAN trial and the authors reply #mmsm @TheLancetHaem ➡️https://t.co/aXpcjG55wz 🧵 https://t.co/rkRELRgw69
9.
ManniMD1
Manni Mohyuddin @ManniMD1
Thank you @MyelomaAmateur and @ManniMD1
This piece is a gem proving that:
patient advocacy critical appraisa… twitter.com/i/web/status/1…
Retweet of status by @Timothee_MD
04 Feb 22 copy & paste +upvote -downvote Thank you @MyelomaAmateur and @ManniMD1 🙏 This piece is a gem 💎 proving that: patient advocacy ↔️critical appraisa… https://t.co/9eqApqEl8m
10.
ManniMD1
Manni Mohyuddin @ManniMD1

Just to take your mind off of omicron long enough to remind you that oncologists have increasing financial COI… twitter.com/i/web/status/1…
Retweet of status by @TheWonkologist
29 Dec 21 copy & paste +upvote -downvote 🚨🚨🚨 Just to take your mind off of omicron long enough to remind you that oncologists have increasing financial COI… https://t.co/yDsjbNkMNC

...but wait! There's more!

1.

fakhright
fakhright @fakhright
astaghfirullah peng.krim guaaaaaaaa..............a *salto sambil solat*
14 Jan 13 copy & paste +upvote -downvote astaghfirullah peng.krim guaaaaaaaa..............a *salto sambil solat* 🙈🙈🙊
https://www.iemoji.com/feed/ManniMD1
Back to top